Verition Fund Management
ACOR

Verition Fund Management’s Acorda Therapeutics ACOR Stock Holding History

Verition Fund Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-682
Closed -$10.5K – 2711
2022
Q4 		$10.5K Hold
682
– – ﹤0.01% 1955
2022
Q3 		$4K Hold
682
– – ﹤0.01% 2957
2022
Q2 		$6K Buy
+682
New +$12.1K ﹤0.01% 2261
2019
Q3 		– Sell
-558
Closed -$513K – 1402
2019
Q2 		$513K Buy
+558
New +$686K 0.01% 658

Other funds holding ACOR

DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
DKP
Davidson Kempner Partners New York $5.16B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Verition Fund Management's ACOR Position: Q1 2023 in Review

Verition Fund Management sold out of Acorda Therapeutics (ACOR) in Q1 2023, closing a stake of 682 shares — an estimated $10.5K sold.

Verition Fund Management first reported a position in ACOR in Q2 2019 and held it in 4 quarters. The position peaked at $513K in Q2 2019. 29 funds tracked by Wall St. Rank hold ACOR as of Q1 2023.

  • Verition Fund Management reported no remaining Acorda Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Verition Fund Management sold 682 Acorda Therapeutics shares in Q1 2023, an estimated $10.5K.
  • Verition Fund Management first reported a position in Acorda Therapeutics in Q2 2019 and held it in 4 quarters.
  • Verition Fund Management's Acorda Therapeutics position peaked at $513K in Q2 2019.
  • 29 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2023.

Based on Verition Fund Management's 13F filing for Q1 2023, filed 15 May 2023.